Duloxetine- A novel therapeutic regimen for trigeminal neuralgia

---

Review Article

Author Details : Akhilanand Chaurasia

Volume : 3, Issue : 4, Year : 2017

Article Page : 222-224

Suggest article by email

Get Permission

---

Abstract

Duloxetine is a potent and selective inhibitor of serotonin and noradrenaline transporters and a weak inhibitor of dopamine transporters. Duloxetine is highly protein bound and is widely distributed throughout tissues. It is rapidly and extensively metabolized in the liver by cytochrome P450 (CYP) 1A2 and 2D6 and its numerous metabolites which are inactive are mainly excreted in the urine. It is more effective for recurrent/refractory type of TN. Duloxetine holds the promise in complete remission of TN in future. So in coming days it may be a drug of choice for medical management of TN. This article is an insight in chemical features, pharmacodynamics, pathophysiology and therapeutics of Duloxetine.

Keywords: Antidepressants, Serotonin uptake inhibitors, Trigeminal Neuralgia, Major depressive disorders

How to cite : Chaurasia A, Duloxetine- A novel therapeutic regimen for trigeminal neuralgia. J Oral Med Oral Surg Oral Pathol Oral Radiol 2017;3(4):222-224

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.